Correction to: Breast Cancer Res
https://doi.org/10.1186/bcr1323
After the publication of this work [1] errors were noticed in Figs. 1a, 6a, and 8a—in which the β-actin bands were mistakenly presented. The corrected Figs. 1, 6, and 8 are presented below. The correction does not affect our conclusions. Nevertheless, we apologize for this error.
Expression levels of Bcl-2 and Bcl-xL proteins in MDA-MB-231, MDA MD-453, BT-474, and ZR-75-1 cells. a Western blot analysis of Bcl-2 and Bcl-xL expression. b Quantification of Bcl-2 and Bcl-xL expression by densitometric analysis. The relative expression of Bcl-2 and BclxL in MDA-MB-453 cells was compared with the expression in MDAMB-231, BT-474, and ZR-75-1 cells. Results are from two representative, independent experiments
Effects of treatment with antisense Bcl-2 and mitomycin C, doxorubicin, paclitaxel, or docetaxel on BT-474 cells. a Expression levels of Bcl-2 and Bcl-xL protein in BT-474 cells transplanted into athymic mice after treatment with antisense (AS) Bcl-2 oligodeoxynucleotides (ODNs) were measured by Western blot analysis at the indicated time points. b Enhancement of the antitumor effects of anticancer drugs by AS Bcl-2 ODNs in BT-474 tumor xenografts. Each point represents the mean tumor volume of the eight mice in each group. Error bars indicate SD. *, P < 0.05, analysis of variance with Fisher's least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxoru- bicin;TXL, paclitaxel; TXT, docetaxel
Effects of treatment with antisense Bcl-xL and mitomycin C, doxorubicin, paclitaxel, or docetaxel on MDA-MB-231 cells. a Expression levels of Bcl-xL and Bcl-2 protein in MDA-MB-231 cells transplanted into athymic mice after treatment with antisense (AS) Bcl-xL oligodeoxynucleotides (ODNs) were measured by Western blot analysis at the indicated time points. b Enhancement of the antitumor effects of anticancer drugs by AS Bcl-xL ODNs in MDA-MB-231 tumor xenografts. Each point represents the mean tumor volume of the four mice in each group. Error bars indicate SD. *, P< 0.05, analysis of variance with Fisher's least significant difference test. The data presented are from two independent experiments. MMC, mitomycin C; DOX, doxorubicin; TXL, paclitaxel; TXT, docetaxel
Reference
Emi, et al. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 2005;7:R940. https://doi.org/10.1186/bcr1323.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Emi, M., Kim, R., Tanabe, K. et al. Correction to: Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 21, 26 (2019). https://doi.org/10.1186/s13058-019-1105-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13058-019-1105-4